Denali Therapeutics Inc. said on 16 February that SAR443820/DNL788, an oral brain-penetrant RIPK1 inhibitor co-developed with Sanofi, failed in the Phase II HIMALAYA clinical trial testing the drug in amyotrophic lateral sclerosis (ALS). The companies have moved three RIPK1 inhibitors into the clinic since entering into a collaboration in 2018 for which Sanofi paid Denali $125m up front, but they have yet to see success beyond Phase I for any of the drug candidates.
Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks
Phase II Trial In Multiple Sclerosis Ongoing
The companies have partnered on the development of RIPK1 inhibitors for multiple indications since 2018, but have yet to see success, having discontinued one of three drugs already.
More from Clinical Trials
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
More from R&D
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.